Related Experiment Video
Updated: Jun 16, 2026
03:37
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
The pharmacokinetics of paliperidone versus risperidone
Jose de Leon1, Gary Wynn, Neil B Sandson
1Mental Health Research Center, Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, USA. jdeleon@uky.edu
Psychosomatics
|February 2, 2010
Summary
This review highlights the pharmacology of risperidone and paliperidone, offering insights into their pharmacokinetics and pharmacodynamics for clinical application. Understanding these atypical antipsychotics aids in optimizing patient treatment and medication management.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Neuroscience
Background:
- Atypical antipsychotics are increasingly available, necessitating broader understanding of their pharmacological profiles.
- Knowledge gaps exist regarding the specific pharmacokinetics and pharmacodynamics of newer agents.
Purpose of the Study:
- To enhance awareness and knowledge of risperidone (R) and paliperidone (9-hydroxyrisperidone [9-OHR]).
- To detail the pharmacokinetics and pharmacodynamics of R and 9-OHR.
Main Methods:
- A comprehensive literature review was conducted on risperidone and 9-hydroxyrisperidone.
- Analysis focused on pharmacokinetic and pharmacodynamic data from in vitro and clinical studies.
Main Results:
- Oral risperidone is approximately twice as potent as oral 9-hydroxyrisperidone.
- The risperidone/9-hydroxyrisperidone ratio indicates CYP2D6 activity, while the concentration-to-dose ratio reflects total body clearance.
- 9-hydroxyrisperidone may have reduced brain penetration due to P-glycoprotein affinity; paliperidone's primary elimination route is renal.
Conclusions:
- Clinicians can utilize risperidone/9-hydroxyrisperidone and concentration-to-dose ratios to interpret plasma levels.
- These ratios provide valuable guidance for optimizing treatment with risperidone and paliperidone.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:10Pharmacokinetics: Overview
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...